Literature DB >> 14634111

OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent.

Rodney A Prell1, Dean E Evans, Colin Thalhofer, Tom Shi, Castle Funatake, Andrew D Weinberg.   

Abstract

Tumor necrosis factor receptor-associated factor 2 (TRAF2), an adapter protein that associates with the cytoplasmic tail of OX40, may play a critical role in OX40-mediated signal transduction. To investigate the in vivo role of TRAF2 in OX40-mediated generation of Ag-specific memory T cells, we bred OVA-specific TCR transgenic mice to TRAF2 dominant-negative (TRAF2 DN) mice. Following Ag stimulation and OX40 engagement of TRAF2 DN T cells in vivo, the number of long-lived OVA-specific T cells and effector T cell function was dramatically reduced when compared with wild-type T cells. We also demonstrate that CTLA-4 is down-regulated following OX40 engagement in vivo and the OX40-specific TRAF2 DN defect was partially overcome by CTLA-4 blockade in vivo. The data provide evidence that TRAF2 is linked to OX40-mediated memory T cell expansion and survival, and point to the down-regulation of CTLA-4 as a possible control element to enhance early T cell expansion through OX40 signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634111     DOI: 10.4049/jimmunol.171.11.5997

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Antigen-independent signalosome of CARMA1, PKCθ, and TNF receptor-associated factor 2 (TRAF2) determines NF-κB signaling in T cells.

Authors:  Takanori So; Pejman Soroosh; So-Young Eun; Amnon Altman; Michael Croft
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 3.  Science gone translational: the OX40 agonist story.

Authors:  Andrew D Weinberg; Nicholas P Morris; Magdalena Kovacsovics-Bankowski; Walter J Urba; Brendan D Curti
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 4.  TRAF family molecules in T cells: Multiple receptors and functions.

Authors:  Tina Arkee; Gail A Bishop
Journal:  J Leukoc Biol       Date:  2019-11-21       Impact factor: 4.962

5.  Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.

Authors:  Jonathan A Roussey; Steven P Viglianti; Seagal Teitz-Tennenbaum; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2017-10-16       Impact factor: 5.422

6.  OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival.

Authors:  Nicole A Vasilevsky; Carl E Ruby; Peter J Hurlin; Andrew D Weinberg
Journal:  Eur J Immunol       Date:  2011-03-14       Impact factor: 5.532

7.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

Review 8.  The role of OX40-mediated co-stimulation in T-cell activation and survival.

Authors:  William L Redmond; Carl E Ruby; Andrew D Weinberg
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

Review 9.  The significance of OX40 and OX40L to T-cell biology and immune disease.

Authors:  Michael Croft; Takanori So; Wei Duan; Pejman Soroosh
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 10.  Integrating costimulatory agonists to optimize immune-based cancer therapies.

Authors:  Angela D Pardee; Amy K Wesa; Walter J Storkus
Journal:  Immunotherapy       Date:  2009-03       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.